EGFR and non-small cell lung carcinoma: This study evaluated the preclinical cardiovascular effects of lazertinib and the cardiac safety of lazertinib treatment of 20 mg to 320 mg in patients with EGFRm locally advanced or metastatic NSCLC who had previously received EGFR TKI treatment.